The White House is taking steps to kill the FDA reform legislation recently passed in the House of Representatives that would require drug companies to publicly post clinical trial results so that doctors, researchers and the public could review them. According to a report in Inside Health Policy, the White House sent congressional staff an “unofficial statement of administration policy” that opposes this provision in the House bill. The blocking of this provision would allow drug companies to continue to conduct their clinical trials in secret, hiding results from the public and cherry picking only those clinical trials they wish to make public.
Consumers Union, the publisher of Consumer Reports, issued a press release warning about this new White House action. Bill Vaughn, a senior health policy with Consumers Union, stated in that press release, “At a time when parents can’t even trust their kids’ toys to be safe, it doesn’t make sense the White House would oppose legislation to help make prescription drugs safer.”